Rigel Pharmaceuticals Inc — Quarterly Cash Flow (NASDAQ:RIGL) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Total assets 139.42 M163.98 M175.97 M206.74 M242.53 M Total liabilities 154.06 M160.69 M157.41 M124.8 M124.92 M Total equity 14.64 M3.29 M18.57 M81.93 M117.61 M Total liabilities & shareholders' equities 139.42 M163.98 M175.97 M206.74 M242.53 M Total debt ————— Net debt —————

Haberler

Earnings Preview: Profound Medical (PROF) Q4 Earnings Expected to Decline

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy?

IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?

Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?

RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?

FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?

Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 (RIGL)

Profound Medical (PROF) Soars 9.5%: Is Further Upside Left in the Stock?

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics